Latest Psychedelic Medicine News

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.